Targeting the EpCAM, prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) antigens of patients with prostate cancer in a single procedure makes the HB-MFP a good tool for collecting CTCs from their blood samples. This evidence concerns the gene FOLH1 and prostate carcinoma.